Trial 0C-22-9


A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Selected Advanced Solid Tumors with Cohort Expansions at the Recommended Phase 2 Dose

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Geeta Iyengar, Coordinator, Xiomara Menendez, R.N., Geeta Iyengar, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Clara Karam, D.M., Maura Fernandez, D.M., Christina Nakhoul, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.